Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
Trade name: Kinrix
Approved
Jun 24, 2008
The DPT vaccine or DTP vaccine is a class of combination vaccines to protect against three infectious diseases in humans: diphtheria, pertussis, and tetanus (lockjaw). The vaccine components include diphtheria and tetanus toxoids, and either killed whole cells of the bacterium that causes pertussis or pertussis antigens. The term toxoid refers to vaccines which use an inactivated toxin produced by the pathogen which they are targeted against to generate an immune response. In this way, the toxoid vaccine generates an immune response which is targeted against the toxin which is produced by the pathogen and causes disease, rather than a vaccine which is targeted against the pathogen itself. The whole cells or antigens will be depicted as either "DTwP" or "DTaP", where the lower-case "w" indicates whole-cell inactivated pertussis and the lower-case "a" stands for "acellular". In comparison to alternative vaccine types, such as live attenuated vaccines, the DTP vaccine does not contain any live pathogen, but rather uses inactivated toxoid to generate an immune response; therefore, there is not a risk of use in populations that are immune compromised since there is not any known risk of causing the disease itself. As a result, the DTP vaccine is considered a safe vaccine to use in anyone and it generates a much more targeted immune response specific for the pathogen of interest. — Wikipedia
Clinical trial activity
108 trials · 47 clinical orgs · 0 marketing orgs
Earliest trial started Sep 1, 2000 (NCT00879827)
Timeline
Indications
Studied for
- Bacterial Infections · Phase 3
- BCG Vaccine · Phase 4
- Dengue · Phase 2
- Dermatitis, Atopic · Phase 2
- Diphtheria · Phase 4
- Diphtheria-Tetanus-acellular Pertussis Vaccines · Phase 3
- Diphtheria Toxoid · Phase 4
- Drugs, Investigational · Phase 2
- Haemophilus Infections · Phase 2
- Haemophilus influenzae · Phase 3
- Haemophilus influenzae type b · Phase 4
- Healthy Volunteers · Phase 3
- Hepatitis A · Phase 3
- Hepatitis A virus · Phase 4
- Hepatitis B · Phase 4
- HIV Infections · Phase 1/Phase 2
- Hypoxia · Phase 3
- Immunity · Phase 4
- Immunization · Phase 4
- Influenza, Human · Phase 2
- Malaria · Phase 3
- Malaria Vaccines · Phase 3
- Measles-Mumps-Rubella Vaccine · Phase 3
- Meninges · Phase 2
- Meningitis · Phase 4
- Meningitis, Bacterial · Phase 3
- Meningococcal Infections · Phase 3
- Meningococcal Vaccines · Phase 2
- Neisseria meningitidis · Phase 4
- Neoplasms, Glandular and Epithelial · Phase 3
- Papillomavirus Infections · Phase 3
- Pertussis Vaccine · Phase 4
- Pneumococcal Infections · Phase 3
- Pneumonia, Staphylococcal · Phase 3
- Poliomyelitis · Phase 4
- Poliovirus · Phase 4
- Poliovirus Vaccines · Phase 4
- Premature Birth · Phase 3
- Rotavirus Infections · Phase 3
- Streptococcal Infections · Phase 4
- Tetanus · Phase 4
- Vaccination · Phase 3
- Vaccine-Preventable Diseases · Phase 2/Phase 3
- Vaccines · Phase 4
- Virus Diseases · Phase 3
- Whooping Cough · Phase 4
- Zika Virus · Phase 1
Mechanism of action
- PoliovirusImmunity, active
Poliovirus immunity, active
- Clostridium tetaniImmunity, active
Clostridium tetani immunity, active
- Bordetella pertussisImmunity, active
Bordetella pertussis immunity, active
- Corynebacterium diphtheriaeImmunity, active
Corynebacterium diphtheriae immunity, active
Approval history
- approvedJun 24, 2008
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDPT vaccine ↗
- WikipediaDTP vaccine ↗
- WikipediaDTaP-IPV vaccine ↗
Also known as
- daptacel
- dpt-ipv
- dtap-ipv mkc vaccine
- gsk217744
- gsk2202083a
- infanrix
- infanrix ipv
- infanrix-ipv/hib
- infanrix penta
- kinrix
- repevax
- revaxis
- tdap-ipv vaccine
- tdcp-ipv vaccine
- tetravac tm
- tetravax-dv
- tetravax-dv-tv003
- tetravax-dv tv005
- tetravax-dv-tv005
- tetraxim
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07203755 | Phase 1 | Oct 22, 2025 | Government of China, Tianjin Cansino Biotechnology Inc |
| NCT07160244 | Phase 3 | Aug 25, 2025 | Pfizer |
| NCT07112144 | Phase 3 | Jun 13, 2025 | Changchun BCHT Biotechnology Co., Government of China |
| NCT06708286 | Phase 2/Phase 3 (Phase 3) | Dec 18, 2024 | Tianjin Cansino Biotechnology Inc |
| NCT06618196 | Phase 2 | Oct 2, 2024 | LG |
| NCT06805487 | Phase 1 | Sep 24, 2024 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT06184542 | Phase 1 | Dec 23, 2023 | Chinese Academy of Medical Sciences, Government of China |
| NCT06344065 | Phase 3 | Dec 21, 2023 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
| NCT05951725 | Phase 3 | Aug 11, 2023 | Tianjin Cansino Biotechnology Inc |
| NCT05155579 | Phase 1 | Feb 28, 2022 | Malaria Research and Training Center, Bamako, Mali, University of Oxford |
| NCT05193734 | Phase 2/Phase 3 (Phase 3) | Feb 7, 2022 | University of Geneva, University of Genoa |
| NCT05116241 | Phase 2 | Nov 30, 2021 | ILiAD Biotechnologies |
| NCT05091619 | Phase 3 | Oct 22, 2021 | Beijing Tiantan Bio Co., Ltd, China National Biotec Group Co., Ltd, Government of China |
| NCT04490018 | Phase 3 | Mar 16, 2021 | Sanofi, Sanofi-Aventis |
| NCT07213089 | Phase 2/Phase 3 (Phase 3) | Jul 13, 2020 | BioNet-Asia Co., Ltd., Mahidol University, National Science and Technology Development Agency, Thailand |
| NCT04429295 | Phase 3 | Jun 29, 2020 | Sanofi-Aventis |
| NCT04300192 | Phase 4 | Mar 9, 2020 | Sanofi, Sanofi-Aventis |
| NCT03891758 | Phase 3 | Apr 1, 2019 | Mitsubishi Tanabe, Osaka University |
| NCT03632720 | Phase 3 | Oct 31, 2018 | Sanofi-Aventis |
| NCT04133987 | Phase 2 | Oct 15, 2018 | Government of Taiwan, National Taiwan University |
Organizations
Research & Development (47)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 48 | 48 | 3 | 2000 |
| Sanofi | For profit | 13 | 12 | 2 | 2001 |
| Sanofi-Aventis | For profit | 12 | 6 | 2 | 2001 |
| Johns Hopkins University | Academic/Hospital | 8 | 0 | 1 | 2010 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 8 | 8 | 1 | 2010 |
| Merck | For profit | 5 | 5 | 2 | 2006 |
| Government of China | Government | 4 | 0 | 2 | 2021 |
| Mitsubishi Tanabe | For profit | 3 | 3 | 2 | 2014 |
| Tianjin Cansino Biotechnology Inc | For profit | 3 | 3 | 2 | 2023 |
| Osaka University | Academic/Hospital | 2 | 0 | 1 | 2016 |
| Pfizer | For profit | 2 | 2 | 2 | 2011 |
| Public Health England | Government | 2 | 2 | 1 | 2013 |
| University of Oxford | Academic/Hospital | 2 | 2 | 2 | 2014 |
| Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | For profit | 1 | 1 | 1 | 2023 |
| Banco Nacional de Desenvolvimento Economico e Social | Government | 1 | 0 | 1 | 2013 |
| Beijing Tiantan Bio Co., Ltd | For profit | 1 | 0 | 1 | 2021 |
| BioNet-Asia Co., Ltd. | For profit | 1 | 1 | 1 | 2020 |
| Butantan Foundation | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Butantan Institute | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Centre Hospitalier le Mans | Academic/Hospital | 1 | 1 | 1 | 2018 |